Why Partner?
500+ drugs in preclinical and clinical trials reference CRISPR as the editing tool. Yet industry decision makers within this established field tell us there remains doubt over who the leading service providers are for their discovery, R&D, preclinical, and clinical programmes.
If you are a contract service provider with expertise in the gene editing drug development field, then CRISPR 2.0 will provide you with the platform to showcase your solutions to a highly engaged and dedicated audience of decision makers from the leading biopharma companies in the space.
Your brand, your message, and your reputation showcased in front of the leading CRISPR experts.
Experts Need Your Help With:
CRISPR constructs,
reagents, enzymes, and
other key technologies
CRISPR-engineered cell
lines, animal models, and
human iPSC lines
Contract manufacturing
organizations and vector
providers
Validated off-target
analytics and sequencing
solutions
2022 Attendees:
Audience Breakdown
“The presentations were of excellent quality and thought-provoking, and touched on many of the key issues relating to CRISPR gene therapy.”
PTC Therapeutics
